Physicians' Academy for Cardiovascular Education

The future of SGLT2i in HF: Managing patients without TDM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD

Efforts to move universal cholesterol screening before the age of 20 forward

3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD

Postive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD

More intelligent intervention through more strategic use of CV biomarkers

3' education - May 28, 2019 - Maastricht, The Netherlands

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, PhD

Why could patients with HF and T2DM benefit from SGLT2i?

10' education - June 12, 2019 - ESC HF 2019 - Prof. Subodh Verma - Toronto, ON, Canada

Growing importance of lowering remnants, also in light of the obesity epidemic

3' education - June 3, 2019 - Børge Nordestgaard

Moving from ignorance on the complexity of HDL to novel therapeutic opportunities

3' education - June 3, 2019 - John Chapman, PhD

ARNI as first-line therapy in de novo HFrEF patients after ADHF event

3' education - June 3, 2019

Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF

3' education - June 3, 2019

Effect of IL-1β inhibition on lung cancer sheds new light on the role of inflammation

3' education - May 28, 2019 - EAS 2019, Maastricht - Paul Ridker, MD

Genetic variants and elevated risk of CAD

3' education - May 28, 2019 - Heribert Schunkert, MD - Munich, Germany

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - May 22, 2019 - ISN-WCN 2019 - Mark Cooper, MD

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada

Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR

3' education - Apr. 17, 2019

Reduction in renal outcomes with selective endothelin receptor antagonist in patients with diabetic kidney disease

3' education - Apr. 17, 2019 - Melbourne, Australia

Endothelin receptor antagonist gives renoprotection in selected patients with T2DM and CKD

3' education - Apr. 15, 2019 - Melbourne, Australia

Higher BMI associated with lower stroke/SEE risk in anticoagulated AF patients

Literature - June 26, 2019 - Boriani G et al., - Eur Heart J. 2019

ENGAGE AF-TIMI 48 data show that BMI was negatively associated with risk of stroke/SEE and positively associated with risk of bleeding, although sex differences were seen.

Blood donor screening as potential strategy for FH screening

Literature - June 25, 2019 - Jackson CL et al. - JAMA Cardiol 2019
In >1 million blood donors, the prevalence of FH was similar to the estimated prevalence of FH in the general population. This suggests that donor screening may represent a new approach for FH screening and intervention.

In >1 million blood donors, the prevalence of FH was similar to the estimated prevalence of FH in the general population. This suggests that donor screening may represent a new approach for FH screening and intervention.

Circulating LDL-c levels associated with early onset Alzheimer disease

Literature - June 25, 2019 - Wingo TS et al., - JAMA Neurol. 2019

Higher LDL-c associates with EOAD, independently of APOE E4. Novel rare genetic coding variants were found in APOB, which do not fully explain the association between high LDL-c and EOAD.

No legacy effect with intensive glucose control for CV outcomes in T2DM after 15 years

Literature - June 25, 2019 - Reaven PD, et al. - N Eng J Med 2019

In the follow-up study of VADT, original intensive glucose lowing over 5.6 years did not result in improved outcomes in T2DM patients vs. standard-therapy after 15 years, providing no evidence of a legacy effect.

Non-fasting and fasting lipid levels linked to similar risk of incident CV events

Literature - June 24, 2019 - Mora S et al. - JAMA Intern Med 2019
An analysis of the ASCOT-LLA trial showed similar associations of non-fasting and fasting lipid levels with CV events in the same individuals, with high concordance for ASCVD risk categorization based on non-fasting and fasting lipid levels.

An analysis of the ASCOT-LLA trial showed similar associations of non-fasting and fasting lipid levels with CV events in the same individuals, with high concordance for ASCVD risk categorization based on non-fasting and fasting lipid levels.

No mortality benefit of beta-blocker in stable CAD beyond one year after MI, according to registry data

Literature - June 24, 2019 - Sorbets E et al., - Eur Heart J. 2019

CLARIFY registry data suggest that beta-blocker use was only associated with lower 5-year mortality in patients enrolled in the year following in MI. Use of calcium antagonists did not impact mortality.

Expert consensus on clinical practice update on HF

News - June 24, 2019

The Heart Failure Association of the ESC has published a clinical practice update on pharmacotherapy, procedures, devices and patient management of heart failure.

The future of SGLT2i in HF: Managing patients without TDM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD
Prof. Adriaan Voors addresses 3 major questions on the future of SGLT2i in HF: on routinely use in T2DM and HF, use in HF without T2DM, and ongoing trials.

Prof. Adriaan Voors addresses 3 major questions on the future of SGLT2i in HF: on routinely use in T2DM and HF, use in HF without T2DM, and ongoing trials.

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore
Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.

Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD
Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.

ISN-WCN 2019 Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.

Efforts to move universal cholesterol screening before the age of 20 forward

3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD
Prof. Kausik Ray talks about the Familial Hypercholesterolemia Studies Collaboration, which was established to address the unmet need to influence global policy change regarding screening for FH patients early in life.

EAS 2019 Prof. Kausik Ray talks about the Familial Hypercholesterolemia Studies Collaboration, which was established to address the unmet need to influence global policy change regarding screening for FH patients early in life.

Postive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD
Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.

EAS 2019 Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.